A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development

被引:165
|
作者
Xie, Jing [1 ]
Farage, Eric [1 ]
Sugimoto, Masahiko [1 ]
Anand-Apte, Bela [1 ,2 ]
机构
[1] Cleveland Clin, Cole Eye Inst, Dept Ophthalm, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA
来源
BMC DEVELOPMENTAL BIOLOGY | 2010年 / 10卷
关键词
ASTROCYTE-ENDOTHELIAL INTERACTIONS; VASCULAR-PERMEABILITY; EXPRESSION; BRADYKININ; PHOSPHORYLATION; VERTEBRATES; MECHANISMS; JUNCTIONS; INTEGRITY; OCCLUDIN;
D O I
10.1186/1471-213X-10-76
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Development and maintenance of the blood-brain and blood-retinal barrier is critical for the homeostasis of brain and retinal tissue. Despite decades of research our knowledge of the formation and maintenance of the blood-brain (BBB) and blood-retinal (BRB) barrier is very limited. We have established an in vivo model to study the development and maintenance of these barriers by generating a transgenic zebrafish line that expresses a vitamin D-binding protein fused with enhanced green fluorescent protein (DBP-EGFP) in blood plasma, as an endogenous tracer. Results: The temporal establishment of the BBB and BRB was examined using this transgenic line and the results were compared with that obtained by injection of fluorescent dyes into the sinus venosus of embryos at various stages of development. We also examined the expression of claudin-5, a component of tight junctions during the first 4 days of development. We observed that the BBB of zebrafish starts to develop by 3 dpf, with expression of claudin-5 in the central arteries preceding it at 2 dpf. The hyaloid vasculature in the zebrafish retina develops a barrier function at 3 dpf, which endows the zebrafish with unique advantages for studying the BRB. Conclusion: Zebrafish embryos develop BBB and BRB function simultaneously by 3 dpf, which is regulated by tight junction proteins. The Tg(l-fabp: DBP-EGFP) zebrafish will have great advantages in studying development and maintenance of the blood-neural barrier, which is a new application for the widely used vertebrate model.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Zebrafish as a Model to Study Drug Transporters at the Blood-Brain Barrier
    Umans, R. A.
    Taylor, M. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) : 567 - 570
  • [22] AN INVITRO MODEL OF THE OUTER BLOOD-RETINAL BARRIER
    ORGUL, S
    PRUNTE, C
    KAIN, HL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1992, 33 (04) : 1126 - 1126
  • [23] Development of the blood-brain barrier
    Britta Engelhardt
    Cell and Tissue Research, 2003, 314 : 119 - 129
  • [24] Development of the blood-brain barrier
    Engelhardt, B
    CELL AND TISSUE RESEARCH, 2003, 314 (01) : 119 - 129
  • [25] THE DEVELOPMENT OF THE BLOOD-BRAIN BARRIER
    LAJTHA, A
    JOURNAL OF NEUROCHEMISTRY, 1957, 1 (03) : 216 - 227
  • [26] Substance Delivery across the Blood-Brain Barrier or the Blood-Retinal Barrier Using Organic Cation Transporter Novel Type 2 (OCTN2)
    Tashima, Toshihiko
    FUTURE PHARMACOLOGY, 2024, 4 (03): : 479 - 493
  • [27] Comparative transcriptome analysis of inner blood-retinal barrier and blood–brain barrier in rats
    Y. Li
    A. Faiz
    H. Moshage
    R. Schubert
    L. Schilling
    J. A. Kamps
    Scientific Reports, 11
  • [28] Role of Extracellular Mycobacteria in Blood-Retinal Barrier Invasion in a Zebrafish Model of Ocular TB
    Damera, Santhosh Kumar
    Panigrahi, Ranjan K.
    Mitra, Sanchita
    Basu, Soumyava
    PATHOGENS, 2021, 10 (03):
  • [29] Novel insights into the development and maintenance of the blood-brain barrier
    Engelhardt, Britta
    Liebner, Stefan
    CELL AND TISSUE RESEARCH, 2014, 355 (03) : 687 - 699
  • [30] Oral Delivery of Bioencapsulated Proteins Across Blood-Brain and Blood-Retinal Barriers
    Kohli, Neha
    Westerveld, Donevan R.
    Ayache, Alexandra C.
    Verma, Amrisha
    Shil, Pollob
    Prasad, Tuhina
    Zhu, Ping
    Chan, Sic L.
    Li, Qiuhong
    Daniell, Henry
    MOLECULAR THERAPY, 2014, 22 (03) : 535 - 546